Peter Lynch · Growth at a reasonable price (GARP)
Is Vertex Pharmaceuticals Incorporated (VRTX) a Peter Lynch Stock?
Some GARP characteristics, but growth or valuation is stretched.
61/100
Mixto
4/6 criterios cumplidos
Los criterios de Peter Lynch, aplicados a VRTX
PEG ≤ 1.0
clave1.85
EPS CAGR ≥ 15%
clave14.2%
Revenue CAGR ≥ 10%
12.4%
Net margin > 0
35.4%
Cómo se valora VRTX en otras estrategias
Datos financieros en vivo
Cap. mercado
$127.93B
PER (TTM)
26.2x
ROIC (TTM)
17.74%
Margen bruto
86.28%
Otros análisis Peter Lynch
Preguntas frecuentes
What is VRTX's Peter Lynch fit score?
VRTX scores 61/100 on our Peter Lynch fit engine. Some GARP characteristics, but growth or valuation is stretched.
Does Peter Lynch actually own VRTX?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends VRTX.
How often is this score updated?
VRTX's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Peter Lynch posea o recomiende VRTX personalmente.
